Cortex Discovery and Mcule have joint their forces to enhance preclinical drug discovery through AI-powered ADME-Tox predictions

January 2025 - Cortex Discovery, a pioneer in AI-driven molecular property prediction, has entered into a collaboration with Mcule, a global supplier of chemical compounds, to advance the speed and accuracy of preclinical drug discovery.
This strategic partnership leverages Cortex Discovery's deep learning system to predict the ADME-Tox (Absorption, Distribution, Metabolism, Excretion, and Toxicity) properties of Mcule's In Stock database, a comprehensive collection of nearly 6 million compounds sourced from more than 110 suppliers. These predictions offer valuable insights into the biological, chemical, and physical characteristics of small molecules, accelerating the selection of promising candidates for further research.

Key Data Generated:
● Aqueous solubility and permeability metrics
● Probabilities of DMSO insolubility
● Inhibitory activity predictions for CYP19A1 and hERG
● Cytotoxicity data for HEK293 cells

"Our collaboration with Mcule marks a significant milestone in preclinical research," said Dr. Ivan de Weber, CEO at Cortex Discovery. "By combining our advanced machine learning algorithms with Mcule's extensive compound library, we are making it easier for researchers to access the critical data they need to make informed decisions early in the drug discovery process."

"Data, whether accurately measured or predicted, is the engine driving drug discovery processes toward effective candidates." said Robert Kiss, CEO of Mcule. "We are honored to collaborate with the agile team at Cortex Discovery to offer this valuable tool for data-driven decision-making."

Mcule.com Kft
Bartók Béla út 105-113., 1115 Budapest, Hungary
contact email: info@mcule.com

About Cortex Discovery
Cortex Discovery is pioneering AI-driven molecular property prediction, offering unprecedented accuracy that rivals experimental results. Our comprehensive suite of solutions includes Virtual High-Throughput Screening (vHTS), ADME-Tox predictions, Off-Target Screening, and Hit Analog Screening. These services enable the parallelization of hit identification and lead optimization, streamlining the drug discovery process with unmatched precision and efficiency.

About Mcule
The chemical marketplaces designed and developed by Mcule offer multi-level solutions for compound sourcing, accelerating drug discovery pipelines. Our curated collection is one of the largest in-stock compound inventories, and we maintain strong partnerships with leading academic institutions, universities, and 12 of the world's top 20 pharmaceutical and biotech companies.

This release was published on openPR.